B16 As a Mouse Model for Human Melanoma

Overview

Journal Curr Protoc Immunol

Specialty Allergy & Immunology

Date 2008 Apr 25

PMID 18432774

Citations 233

Authors

W W Overwijk

N P Restifo

Affiliations

Soon will be listed here.

Abstract

This unit details protocols for in vivo models of subcutaneous growth and pulmonary metastases of B16 melanoma. Therapeutic approaches include the use of B16.GM-CSF and rVVmTRP-1 to induce autoimmune vitiligo and tumor protection. The induction and use of gp 100-specific therapeutic cytotoxic T lymphocytes (CTL) are discussed. Methods are also included for CTL induction, isolation and testing, CTL maintenance, and adoptive transfer. Support protocols detail the testing of mouse sera for presence of MDA-specific antibodies by immunoblotting and ELISA, respectively. Additional sections, including growing B16 melanoma, enumerating pulmonary metastases, and use of recombinant viruses for vaccination, are discussed together with safety concerns.

Citing Articles

Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy.

Mehta A, Motavaf M, Nebo I, Luyten S, Osei-Opare K, Gru A J Clin Med. 2025; 14(4).

PMID: 40004731 PMC: 11856346. DOI: 10.3390/jcm14041200.

Targeted intra-tumoral hyperthermia using uniquely biocompatible gold nanorods induces strong immunogenic cell death in two immunogenically 'cold' tumor models.

Kennedy B, Noftall E, Dean C, Roth A, Clark K, Rowles D Front Immunol. 2025; 15:1512543.

PMID: 39872527 PMC: 11769938. DOI: 10.3389/fimmu.2024.1512543.

Systemic IFN-I combined with topical TLR7/8 agonists promotes distant tumor suppression by c-Jun-dependent IL-12 expression in dendritic cells.

Sanlorenzo M, Novoszel P, Vujic I, Gastaldi T, Hammer M, Fari O Nat Cancer. 2025; 6(1):175-193.

PMID: 39849091 PMC: 11779648. DOI: 10.1038/s43018-024-00889-9.

Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung.

Zhu T, Xiao Y, Chen Z, Ding H, Chen S, Jiang G Nat Commun. 2025; 16(1):262.

PMID: 39747173 PMC: 11695690. DOI: 10.1038/s41467-024-55751-4.

Flotillin-2 dampens T cell antigen sensitivity and functionality.

Moon S, Zhao F, Uddin M, Tucker C, Karmaus P, Fessler M JCI Insight. 2024; 9(24).

PMID: 39499901 PMC: 11665568. DOI: 10.1172/jci.insight.182328.

References

Wang R, Parkhurst M, Kawakami Y, Robbins P, Rosenberg S . Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med. 1996; 183(3):1131-40. PMC: 2192321. DOI: 10.1084/jem.183.3.1131. View

Wu T, Huang A, Jaffee E, Levitsky H, Pardoll D . A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med. 1995; 182(5):1415-21. PMC: 2192183. DOI: 10.1084/jem.182.5.1415. View

Hart I . The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol. 1979; 97(3):587-600. PMC: 2042430. View

Overwijk W, Lee D, Surman D, Irvine K, Touloukian C, Chan C . Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A. 1999; 96(6):2982-7. PMC: 15881. DOI: 10.1073/pnas.96.6.2982. View

Fidler I, Gersten D, Budmen M . Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res. 1976; 36(9 pt.1):3160-5. View

Donawho C, Muller H, Bucana C, Kripke M . Enhanced growth of murine melanoma in ultraviolet-irradiated skin is associated with local inhibition of immune effector mechanisms. J Immunol. 1996; 157(2):781-6. View

Overwijk W, Tsung A, Irvine K, Parkhurst M, Goletz T, Tsung K . gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998; 188(2):277-86. PMC: 2212458. DOI: 10.1084/jem.188.2.277. View

Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde K . Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994; 24(3):759-64. DOI: 10.1002/eji.1830240340. View

Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I . Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994; 179(2):523-32. PMC: 2191382. DOI: 10.1084/jem.179.2.523. View

10.

Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E . Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol. 1997; 158(4):1796-802. View

11.

Kawakami Y, Robbins P, Wang X, Tupesis J, Parkhurst M, Kang X . Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998; 161(12):6985-92. View

12.

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539-43. PMC: 46336. DOI: 10.1073/pnas.90.8.3539. View

13.

Kang X, Kawakami Y, Wang R, Sakaguchi K, Yannelli J, Appella E . Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol. 1995; 155(3):1343-8. View

14.

Li M, Xu F, Muller J, Hearing V, Gorelik E . Ecotropic C-type retrovirus of B16 melanoma and malignant transformation of normal melanocytes. Int J Cancer. 1998; 76(3):430-6. DOI: 10.1002/(sici)1097-0215(19980504)76:3<430::aid-ijc23>3.0.co;2-d. View

15.

Irvine K, Chamberlain R, Shulman E, Surman D, Rosenberg S, Restifo N . Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst. 1997; 89(21):1595-601. DOI: 10.1093/jnci/89.21.1595. View

16.

Touloukian C, Leitner W, Topalian S, Li Y, Robbins P, Rosenberg S . Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 2000; 164(7):3535-42. PMC: 2241739. DOI: 10.4049/jimmunol.164.7.3535. View

17.

Kawakami Y, Eliyahu S, Sakaguchi K, Robbins P, Rivoltini L, Yannelli J . Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180(1):347-52. PMC: 2191573. DOI: 10.1084/jem.180.1.347. View

18.

van Elsas A, Hurwitz A, Allison J . Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors.... J Exp Med. 1999; 190(3):355-66. PMC: 2195583. DOI: 10.1084/jem.190.3.355. View

19.

Otsuka T, Takayama H, Sharp R, Celli G, LaRochelle W, Bottaro D . c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 1998; 58(22):5157-67. View

20.

Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J . T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol. 1998; 161(2):897-908. View